Researchers developed a computational model to study aging in 40 types of human tissue, identifying three major aging patterns and underlying molecular changes. Tissues show bimodal structural aging, with accelerated aging from 35-40 and 55-60, coinciding with fertility decline and menopause.
Cyclin D1, a protein linked to cancer, paradoxically promotes chronic inflammation in non-proliferating senescent cells, which can lead to age-related disease. Research suggests that targeting cyclin D1 may be a promising strategy to reduce inflammation and promote healthier aging.
Scientists have discovered a new connection between energy-producing mitochondria and chronic inflammation in senescent cells, which promotes age-related diseases. Blocking a related gene and using a drug called CTPI-2 reduced inflammation and promoted healthier aging in mice.
Researchers create unified framework to explain MYC gene's role in cancer, identifying potential therapeutic targets. The MYC gene is a master regulator controlling cell growth, division, and metabolism, and is frequently altered in human cancer. A new study identifies PVT1 as a key regulatory hub for MYC activity, encoding two novel p...
Cancer cells' ability to evade the immune system is linked to changes in their surrounding environment, including nearby nutrients and conditions. Researchers discovered that altering these factors can thin the cancer cell's protective sugar coating, allowing the immune system to recognize and eliminate them.
Scientists have uncovered a new mechanism used by heart cells to resist reprogramming and found that carbohydrate sulfotransferase 7 (CHST7) is the most potent preventer of reprogramming in mouse and human cells. By targeting CHST7, researchers may develop treatments to help the heart fix itself after injury.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found significant sex-based protein differences in lung adenocarcinoma, with 901 proteins varying between male and female patient samples. This study contributes to understanding cancer biology and may benefit physicians and patients.
A new study by Sanford Burnham Prebys found that bolstering the SORLA protein can reduce tau tangle toxicity, a common culprit in Alzheimer's disease and other neurodegenerative disorders. This suggests potential as a therapeutic strategy for treating these conditions.
Jill Mesirov brings expertise in computational biology and genomics to Sanford Burnham Prebys, aiming to advance cancer research and treatment. She will mentor next-gen computational biologists and leverage AI tools to personalize therapy.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that enhancing protein-folding processes can help prevent harm to insulin-producing cells. The study revealed the importance of a chaperone protein called binding immunoglobulin protein and its cochaperone protein p58 IPK in maintaining proper proinsulin folding.
Researchers identified key factors, including diet, exercise, stress, and social engagement, that contribute to the long lives of Cilento residents. The CIAO Study aims to inform clinical solutions by providing actionable answers on aging and longevity.
Researchers used patient-derived xenograft (PDX) models to study deadly DNA loops in cancer cells. They found significant similarities between human tumor samples and PDX models, including consistent presence of extra copies of oncogenes. These findings suggest that ecDNA-positive tumor cells may drive tumor growth and recurrence.
Researchers discover that kinases play a crucial role in moving cholesterol to activate a growth pathway in aggressive cancers. Without these enzymes, cancer cells are blocked from fueling tumor growth. The study highlights the importance of targeting lipid enzymes as a potential treatment strategy for cancers with TP53 mutations.
Sanford Burnham Prebys receives a $5 million gift from Andrew Viterbi to advance its Center for Data Science and Artificial Intelligence. The center is exploring raw or untapped data to uncover patterns and insights that can inform scientists and clinicians.
A multi-institutional team led by Sanford Burnham Prebys aims to develop a non-opioid pain therapeutic using lead molecule SBI-810. The effort, funded by a $3.9 million NIH grant, seeks to optimize the compound into a drug that could provide effective pain relief without addiction risks.
Researchers studying RNA pollution's impact on aging brains seek to develop therapeutic strategies for neurodegenerative diseases like Alzheimer's. Sanford Burnham Prebys scientist Anne Bang will use advanced robotics to test thousands of compounds.
Scientists have discovered a new rare genetic disease caused by a mutation in the RPN1 gene, which affects glycosylation and leads to protein instability. The disease, now termed RPN1-CDG, is characterized by neurodevelopmental issues and has expanded the number of genes associated with OST complex diseases.
Researchers define a new genetic disease marked by premature aging and brain function deficits, tracing the cause to a mutated IVNS1ABP gene. The study uses genome sequencing and cellular reprogramming to identify potential treatment targets.
A new tool, metapipeline-DNA, automates and standardizes genome sequencing analysis, reducing the complexity of large and complicated data. The open-access resource, developed by Sanford Burnham Prebys and the University of California Los Angeles, aims to improve collaboration and reproducibility across research labs.
Researchers developed a computational tool that infers telomere length from structural changes in cells and tissues captured in medical biopsies. The TLPath model accurately predicts telomere length, providing new opportunities for studying human aging.
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
Researchers created a simplified, scalable human cell model to study coordinated brain rhythms. They found that inhibitory signaling mediated by GABA helped promote sleep and prevent seizures, while potassium channel perturbations influenced rhythmic organization in distinct ways.
Researchers developed new chemical probes to track individual enzymes, enabling direct measurement of protein activity and correcting prior limitations. This allows for a clearer picture of molecular logic in cells undergoing programmed cell death, potentially informing drug discovery.
Researchers at Sanford Burnham Prebys found that transplanted stem cells develop neurons with unique codes to navigate and form connections in the brain. These codes guide the growth of axons and explain why most neurons of a particular subtype send axons to specific brain regions.
Researchers found that the tenascin-C protein promotes a thriving community of functional muscle stem cells needed for efficient muscle regeneration. Aging reduces skeletal muscle regeneration due to lower levels of TnC and impaired muscle stem cell function.
Researchers discover GFAP's crucial role in regulating mitochondrial fusion and fission, a dynamic process that meets cells' energy needs. The study sheds light on Alexander disease, a genetic disorder caused by GFAP mutations, providing potential new avenues for therapies.
A new computational tool called DeepTarget predicts direct and indirect targets of cancer drugs, revealing that small molecules can have different targets and effects depending on the disease and cell type. The study demonstrates the tool's superior performance in real-world scenarios, highlighting its potential to accelerate drug deve...
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that aging accelerates pancreatic cancer progression, leading to faster tumor growth and metastasis. By understanding the impact of age on the tumor microenvironment, they developed a new approach to treating this disease in frail patients.
Researchers used an experimental evolution approach to map genetic mutations in A. baumannii treated with tigecycline and colistin, confirming and extending existing knowledge on major mechanisms of resistance. The study's findings aim to develop genomics-based predictions of drug resistance and susceptibility.
Researchers at Sanford Burnham Prebys have developed a new method to generate more and potent skeletal muscle progenitor cells. The study found that blocking the activity of Janus kinase 2 (JAK2) yields a twofold increase in cell yield, while also delivering more mature and effective cells for regenerative medicine treatment.
Researchers used CRISPR technology to identify HMGN1, a nuclear binding protein that contributes to trisomy 21-related CHDs. The study found that an overabundance of HMGN1 leads to abnormal heart development and gene expression.
Researchers at Sanford Burnham Prebys discovered a new mechanism to confer signaling bias in predictable ways, permitting rational design of new drugs. This breakthrough could lead to better therapies for addiction and psychiatric disorders by targeting the neurotensin receptor 1 (NTSR1) with biased modulators.
Paul Boutros, a pioneer in using AI and machine learning to analyze cancer data, is appointed as the new director of the National Cancer Institute-designated cancer center at Sanford Burnham Prebys. The cancer center will leverage computational tools to personalize therapies for cancer patients.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that using a drug as a blocker to outcompete the SUMO2 protein may be a winning strategy against synovial sarcoma. This approach aims to reverse aberrant epigenetic rewiring driven by the SS18::SSX fusion oncoproteins and impair sarcomagenesis.
Cancer cells with abundant circular DNA elements (ecDNA) carrying oncogenes like MYCN are resistant to chemotherapy. Combining standard chemotherapy with a secondary therapy targeting these senescent cells leads to improved outcomes in mouse models of neuroblastoma and medulloblastoma.
Scientists have discovered that MYOD protein can act as a gene silencer, clearing out old 'furniture' to reset the cell's identity. This finding challenges dogma and opens up new avenues for understanding cellular reprogramming and regenerative medicine therapies.
Researchers identified hundreds of hidden binding partners for a blood protein receptor, revealing links to organ dysfunction and increased sepsis risk. The study found that Mrc1's absence led to the accumulation of mannosylated proteins, which disrupted normal physiology and function.
Researchers at Sanford Burnham Prebys found that blocking macropinocytosis reshapes the tumor microenvironment, allowing more access to immune cells. This change made immunotherapy and chemotherapy more effective in treating PDAC tumors in mice.
Researchers created an 'encyclopedia of sugar utilization pathways' in 263 Bifidobacterium genomes. This resource helps predict which strains thrive in different conditions, enabling personalized probiotics to match children's lifestyles and dietary needs. The study suggests a potential solution to improving outcomes for preterm infants.
A new approach for understanding chromatin's 3D structure and its influence on gene regulation has been developed by scientists at Sanford Burnham Prebys. The method measures a genomic region's proximity to the isolated center of a chromatin clump, revealing that surface regions are more active than core regions.
Michael Karin, renowned for his work on chronic inflammation and cancer, will lead the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys. He aims to develop new treatments for metabolic and liver diseases, which affect millions of patients worldwide.
Researchers identified novel truncated RNAs from jumping genes that encode reverse transcriptases in the aging human brain, particularly in neurons. This discovery may provide new insights into Alzheimer's disease and potential therapeutic targets.
The CIAO study found that centenarians in Cilento, Italy, adhere to a Mediterranean diet rich in fresh fruits, vegetables, and olive oil, which pays health dividends. They also exhibit coordinated immune responses and social engagement, maintaining cognitive integrity and emotional stability.
Researchers have reexamined the Ashwell-Morell receptor's functions using innovative glycoengineering techniques, clarifying its roles in sepsis and inflammation control. The study reveals that the receptor can bind to a specific type of protein glycan chain, which was previously thought to be incompatible with binding.
Researchers will gather in Italy to review a decade of work on promoting healthy aging and extreme longevity. The study aims to identify key factors that contribute to the remarkable health of residents over 100 years old.
Cells dynamically adjust nuclear pore complexes like a retail store opening more checkout lines to regulate genome access. Research findings suggest that protein creation and disposal systems control the amount of NPCs in cells.
Scientists at Sanford Burnham Prebys developed a new method of generating antibodies by fusing two immune system proteins, enabling the creation of stable monoclonal antibodies. This breakthrough has potential applications in diagnosing and monitoring diseases such as lupus and cancers.
Senescent cells can cause chronic inflammation through the secretion of inflammatory molecules, leading to age-related diseases. The study found that a cellular circuit controlling DNA repair can suppress this inflammation, offering potential ways to promote healthier aging.
Scientists at Sanford Burnham Prebys discovered novel fragments of future drugs that selectively inhibit the enzyme VHR, which plays a role in controlling the immune system's response to danger. The findings may lead to the development of new therapies for sepsis and septic shock.
Researchers at Sanford Burnham Prebys have discovered a way to target the energy supply chain of cancer cells. By understanding how enzymes like ubiquitous mitochondrial creatine kinase (uMtCK) function, scientists can design new treatments that slow or stop tumor growth.